Disease Information

General Information of the Disease (ID: DIS00377)

• Name: Juvenile myelomonocytic leukaemia
• ICD: ICD-11: 2A42

Type(s) of Resistant Mechanism of This Disease

  UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Drug

Preclinical Drug(s) 1 drug(s) in total

Cryptotanshinone

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Unusual Activation of Pro-survival Pathway (UAPP)

Key Molecule: Tyrosine-protein phosphatase non-receptor type 11 (PTPN11) [1]

• Sensitive Disease: Juvenile myelomonocytic leukaemia [ICD-11: 2A42.0]
• Molecule Alteration: Missense mutation; p.E76K (c.226G>A)
• Sensitive Drug: Cryptotanshinone
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: Ba/F3 cells; Colon; Homo sapiens (Human); CVCL_0161
• Experiment for Molecule Alteration: Western blotting analysis
• Experiment for Drug Resistance: CellTiter 96 aqueous one solution cell proliferation assay
• Mechanism Description: The missense mutation p.E76K (c.226G>A) in gene PTPN11 cause the sensitivity of Cryptotanshinone by unusual activation of pro-survival pathway

References

• Ref 1: Identification of cryptotanshinone as an inhibitor of oncogenic protein tyrosine phosphatase SHP2 (PTPN11)J Med Chem. 2013 Sep 26;56(18):7212-21. doi: 10.1021/jm400474r. Epub 2013 Sep 4.